Advancing ADC Development: From Characterization to Bioanalysis
About This Webcast
Advancing ADC Development: From Characterization to Bioanalysis 🕙Time: 10 AM PT | 1 PM ET | 5 PM GMT | 7 PM CET Featured Talk "Bioanalysis Strategies of Antibody Drug Conjugates" Introduction Antibody-drug conjugates (ADCs) combine the targeting capabilities of antibodies with the potent activity of cytotoxic payloads, creating unique analytical challenges throughout drug development. Robust bioanalytical strategies are essential for characterizing ADC binding properties and addressing critical challenges in pharmacokinetic (PK) assessment. Highlights Target and Fc receptor binding characterization using SPR/BLI Key PK bioanalysis challenges, including DAR sensitivity and payload biotransformation Soluble target interference and ADA assessment Streamlined bioanalytical solutions for ADC development
Speakers
Jialing Zhang, PhD.
Senior Product Manager , ACROBiosystems
Dr. Jialing Zhang holds a Ph.D. with extensive research and industry experience in anttibody-drug conjugates (ADCs). She currently serves as the Product Manager for the ADC product line at ACROBiosystems, overseeing product strategy and technical solutions across the ADC developmeent life.